DOCSLIB.ORG

Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children with Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

This is a repository copy of Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-induced Nausea and Vomiting in Children with Cancer. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/97043/ Version: Accepted Version Article: Flank, Jaqueline, Robinson, Paula, Holdsworth, Mark et al. (7 more authors) (2016) Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-induced Nausea and Vomiting in Children with Cancer. Pediatric blood & cancer. ISSN 1545-5009 https://doi.org/10.1002/pbc.25955 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Pediatric Blood & Cancer Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-induced Nausea and Vomiting in Children with Cancer Journal: Pediatric Blood & Cancer Manuscript ID PBC-15-1233.R1 Wiley - ManuscriptFor type: Clinical Peer Practice Gui elinesReview Date Submitte by the Author: n/a Complete List of Authors: Flank, Jac,ueline- .he /ospital for Sick Chil ren, Pharmacy- 0ni1ersity of .oronto, Leslie Dan Faculty of Pharmacy Robinson, Paula- Pe iatric 2ncology Group of 2ntario, /ol sworth, Mark- 0ni1ersity of New Me6ico, College of Pharmacy Phillips, Robert- 0ni1ersity of 7ork, Centre for Re1iews an Dissemination- Lee s .eaching /ospitals N/S .rust, Department of Pae iatric /aematology an 2ncology Portwine, Carol- McMaster 0ni1ersity, Pae iatrics Gibson, Paul- Chil ren8s /ospital, Lon on /ealth Sciences Centre, Di1ision of Pe iatric /ematology an 2ncology Maan, Cathy- Chil ren8s /ospital, Lon on /ealth Sciences Centre, Di1ision of Pe iatric /ematology an 2ncology Stefin, Nancy- McMaster 0ni1ersity, Pae iatrics Sung, Lillian- /ospital for Sick Chil ren, Pe iatrics Dupuis, L.Lee- .he /ospital for Sick Chil ren, Pharmacy- chemotherapy-in uce 1omiting, chemotherapy-in uce nausea, 9eywor s: supporti1e care, clinical practice gui eline John Wiley & Sons Page 1 of 72 Pediatric Blood & Cancer 1 Guideline for the Treatment of Breakthrough and the Prevention of Refractory 2 Chemotherapy-induced Nausea and Vomiting in Children with Cancer 3 4 J. Flank,1,2 P.D. Robinson,3 M. Holdsworth,4 R. Phillips,5,6 C. Portwine,7 P. Gibson,8 C. Maan,8 5 N. Stefin,7 L. Sung,9,10 L.L. Dupuis1,2,10 6 7 1Department of Pharmacy, The Hospital for Sick Children, Toronto, Canada 8 2Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada 9 3Pediatric Oncology GroupFor of Ontario, Peer Toronto, CanadReviewa 10 4 College of Pharmacy, University of New Mexico, Albuquerque, New Mexico, USA 11 5Regional Department of Haematology and Oncology, Leeds Children’s Hospital, Leeds, United 12 Kingdom 13 6Centre for Reviews and Dissemination, University of York, York, United Kingdom 14 7Division of Hematology/Oncology, Department of Pediatrics, McMaster University, Hamilton, 15 Canada 16 8 Pediatric Hematology/Oncology, Children’s Hospital, London Health Sciences Centre, London, 17 Canada 18 9 Department of Paediatrics, Division of Haematology/Oncology, The Hospital for Sick 19 Children, Toronto, Canada 20 10Research Institute, The Hospital for Sick Children, Toronto, Canada 21 22 Corresponding Author: L. Lee Dupuis 23 Research Institute 24 The Hospital for Sick Children 25 555 University Ave 26 Toronto, ON 27 Canada M5G 1X8 28 [email protected] John Wiley & Sons 1 Pediatric Blood & Cancer Page 2 of 72 29 phone: 416-813-7654 3t 309355 30 fa3: 416-813-5979 31 Abstract word count: 86 32 Main T 3t word count: 4,468 33 Tabl s: 3 Figur s: 1 Suppl m ntal Fil s: 1 34 Running Titl : Br akthrough & R fractor. Naus a and Aomiting 35 7 . words: ch moth rap.-induc d 1omiting, ch moth rap.-induc d naus a, supporti1 car , 36 clinical practic guid lin 37 For Peer Review 38 39 Abbr 1iation Full T rm CINA Ch moth rap.-induc d naus a and 1omiting CIA Ch moth rap.-induc d 1omiting EPS E3trap.ramidal s.mptoms HEC Highl. m tog nic ch moth rap. MEC Mod rat l. m tog nic ch moth rap. 40 John Wiley & Sons 2 Page 3 of 72 Pediatric Blood & Cancer 41 Abstract 42 This clinical practic guid lin pro1id s an approach to th tr atm nt of br akthrough 43 ch moth rap.-induc d naus a and 1omiting CCINAD and th pr 1 ntion of r fractor. CINA in 44 childr n. It was d 1 lop d b. an int rnational, int r-prof ssional pan l and is bas d on 45 s.st matic lit ratur r 1i ws. E1id nc -bas d int r1 ntions for tr atm nt of br akthrough and 46 proph.la3is of r fractor. CINA ar r comm nd d. Gaps in th 1id nc us d to support th 47 r comm ndations mad in this clinical practic guid lin w r id ntifi d. Th contribution of 48 th s r comm ndations to br akthrough and r fractor. CINA control in childr n r 5uir s 49 prosp cti1 1aluation.For Peer Review 50 51 52 53 John Wiley & Sons 3 Pediatric Blood & Cancer Page 4 of 72 54 ntroduction 55 Childr n commonl. 3p ri nc ch moth rap.-induc d naus a and 1omiting CCINAD d spit 56 administration of mod rn, guid lin -consist nt anti m tic ag nts. Childr n who 3p ri nc 57 CINA in pr 1ious ch moth rap. blocks d spit administration of proph.la3is Cbr akthrough 58 CINAD which do s not r spond to tr atm nt or to chang s in CINA proph.la3is ar d m d to 59 ha1 r fractor. CINA. Achi 1ing compl t CINA control ma. b mor difficult in th s 60 pati ntsE1F and finding ff cti1 anti m tic int r1 ntions for th m can b chall nging. An 61 1id nc -bas d approach to optimiGing CINA control in th s pati nts is th r for ss ntial. 62 For Peer Review 63 Th o1 rall obH cti1 of this clinical practic guid lin is to optimiG br akthrough and 64 r fractor. CINA control in childr n. This guid lin appli s to childr n ag d 1 month to 18 . ars 65 r c i1ing ch moth rap.. Th targ t us rs of this guid lin ar all h althcar pro1id rs who car 66 for th s childr n. For th purpos of this guid lin , optimal control of br akthrough CINA is 67 d fin d as acut r li f of naus a or 1omiting during th curr nt ch moth rap. block. 2ptimal 68 control of r fractor. CINA is d fin d as no 1omiting, no r tching, no naus a, no us of 69 anti m tic ag nts oth r than thos gi1 n for CINA pr 1 ntion and no naus a-r lat d chang in 70 th child6s usual app tit and di t. 71 72 This guid lin r pr s nts th fourth guid lin in a s ri s to addr ss CINA in childr n. Th thr 73 pr 1iousl. publish d guid lin s addr ss ch moth rap. m tog nicit., pr 1 ntion of acut 74 CINAand manag m nt of anticipator. CINA in childr n with canc r.E2-4F Compl t 1 rsions of 75 all four guid lin s ma. b 1i w d at: http:99www.pogo.ca9h althcar 9practic guid lin s9. 2ur 76 r comm ndations ar bas d on th assumption that childr n ar r c i1ing CINA proph.la3is that 77 is consist nt with th pr 1iousl. publish d guid lin s. 78 79 Methods 80 Guid lin pan l and d 1 lopm nt of clinical 5u stions 81 Guid lin pan l m mb rs w r chos n to r pr s nt int r-prof ssional staff from P diatric 82 2ncolog. Group of 2ntario c nt rs and from int rnationall. r cogniG d 3p rts in p diatric 83 supporti1 car . 2nc chos n, th pan l m mb rs d 1 lop d th sp cific h alth 5u stions CTabl 84 ID to b addr ss d b. this guid lin . John Wiley & Sons 4 Page 5 of 72 Pediatric Blood & Cancer 85 86 S.st matic lit ratur s arch s 87 In March 2015, comput riG d s arch s CSuppl m ntar. Tabl ID w r p rform d with th 88 assistanc of a librar. sci ntist to id ntif. guid lin s which could b ndors d for th tr atm nt 89 of br akthrough CINA and for th pr 1 ntion of r fractor. CINA in childr n. 4,451 citations 90 w r id ntifi d and scr n d. Sinc non m t th inclusion crit ria CTabl IID for ndors m nt 91 ass ssm nt, th guid lin pan l proc d d to d 1 lop a de novo guid lin .
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al

    US 2006.0024.365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya et al. (43) Pub. Date: Feb. 2, 2006 (54) NOVEL DOSAGE FORM (30) Foreign Application Priority Data (76) Inventors: Navin Vaya, Gujarat (IN); Rajesh Aug. 5, 2002 (IN)................................. 699/MUM/2002 Singh Karan, Gujarat (IN); Sunil Aug. 5, 2002 (IN). ... 697/MUM/2002 Sadanand, Gujarat (IN); Vinod Kumar Jan. 22, 2003 (IN)................................... 80/MUM/2003 Gupta, Gujarat (IN) Jan. 22, 2003 (IN)................................... 82/MUM/2003 Correspondence Address: Publication Classification HEDMAN & COSTIGAN P.C. (51) Int. Cl. 1185 AVENUE OF THE AMERICAS A6IK 9/22 (2006.01) NEW YORK, NY 10036 (US) (52) U.S. Cl. .............................................................. 424/468 (22) Filed: May 19, 2005 A dosage form comprising of a high dose, high Solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of Related U.S. Application Data immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of (63) Continuation-in-part of application No. 10/630,446, modified release active ingredient per unit is from 500 mg to filed on Jul. 29, 2003. 1500 mg, a process for preparing the dosage form. Patent Application Publication Feb. 2, 2006 Sheet 1 of 10 US 2006/0024.365A1 FIGURE 1 FIGURE 2 FIGURE 3 Patent Application Publication Feb. 2, 2006 Sheet 2 of 10 US 2006/0024.365A1 FIGURE 4 (a) 7 FIGURE 4 (b) Patent Application Publication Feb. 2, 2006 Sheet 3 of 10 US 2006/0024.365 A1 FIGURE 5 100 ov -- 60 40 20 C 2 4.
  • Blood Thinners These Medications Require up to 2 Weeks of Discontinued Use Prior to a Myelogram Procedure

    Blood Thinners These Medications Require up to 2 Weeks of Discontinued Use Prior to a Myelogram Procedure

    MEDICATIONS TO AVOID PRE & POST MYELOGRAMS Radiocontrast agents used in myelography have the ability to lower the seizure threshold and when used with other drugs that also have this ability, may lead to convulsions. Drugs that possess the ability to lower seizure threshold should be discontinued at least 48 hours prior to myelography if possible and should not be resumed until at least 24 hours post-procedure. Drugs are listed below. ***Always consult with your prescribing physician prior to stoppage of your medication. Phenothiazines Antidepressants MAO Inhibitors Acetophenazine (Tindal) Amitriptyline (Elavil) Furazolidone (Furoxone) Chlorpromazine (Thorazine) Amoxapine (Asendin) Isocarboxazid (Marplan) Promethazine (Phenergan) Bupropion *(Welbutrin, Zyban) Pargyline (Eutonyl) Ethopropazine (Parsidol) Clomipramine (Anafranil, Placil) Phenelzine (Nardil) Fluphenazine (Prolixin) Desipramine (Norapramin) Procarbazine (Matulane) Mesoridazine (Serentil) Doxepin (Sinequan) Tranlcypromine (Parnate) Methdilazine (Tacaryl) Imipramine (Tofranil) Perphenazine (Trilafon) Maprotiline (Ludiomil) CNS Stimulants Proclorperazine (Compazine) Nortriptyline (Pamelor) Amphetamines Promazine (Sparine) Protriptyline (Vivactil) Pemoline (Cylert) Promethazine (Phenergan) Trimipramine (Surmontil) Thiethylperazine (Torecan) Thioridazine (Mellaril) Combination Antidepressants Trifluoperazine (Stelazine) Amitriptyline + Chlordiazepoxide (Limbitrol DS) Triflupromazine (Vesprin) Amitriptyline + Perphenazine (Triavil) Largon Levoprome Miscellaneous Antipsychotics
  • Drug and Medication Classification Schedule

    Drug and Medication Classification Schedule

    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available

    BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available

    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
  • CPT / HCPCS Code Drug Description Approximate Cost Share

    CPT / HCPCS Code Drug Description Approximate Cost Share

    The information listed here is for our most prevalent plan. The amount you pay for a covered drug will depend on your plan’s coverage. Please refer to your Medical Plan GTB for more information. To find out the cost of your drugs, please contact HMSA Customer Service at 1-800-776-4672. If you receive services from a nonparticipating provider, you are responsible for a copayment plus any difference between the actual charge and the eligible charge. Legend $0 = no cost share $ = $100 and under $$ = over $100 to $250 $$$ = over $250 to $500 $$$$ = over $500 to $1000 $$$$$ = over $1000 1 = Please call HMSA Customer Service 1-800-776-4672 for cost share information. 2 = The cost share for this drug is dependent upon the diagnosis. Please call HMSA Customer Service at 1-800-772-4672 for more information. 3 = Cost share information for these drugs is dependent upon the dose prescribed. Please call HMSA Customer Service at 1- 800-772-4672 for more information. CPT / HCPCS approximate Code Drug Description cost share J0129 Abatacept Injection $$$$ J0130 Abciximab Injection 3 J0131 Acetaminophen Injection $ J0132 Acetylcysteine Injection $ J0133 Acyclovir Injection $ J0135 Adalimumab Injection $$$$ J0153 Adenosine Inj 1Mg $ J0171 Adrenalin Epinephrine Inject $ J0178 Aflibercept Injection $$$ J0180 Agalsidase Beta Injection 3 J0200 Alatrofloxacin Mesylate 3 J0205 Alglucerase Injection 3 J0207 Amifostine 3 J0210 Methyldopate Hcl Injection 3 J0215 Alefacept 3 J0220 Alglucosidase Alfa Injection 3 J0221 Lumizyme Injection 3 J0256 Alpha 1 Proteinase Inhibitor
  • 2004 Guide to Psychiatric Drug Interactions Sheldon H

    2004 Guide to Psychiatric Drug Interactions Sheldon H

    Av Referencein Pocketailable Format —pg. 59 Educational Review Primary Psychiatry. 2004;11(2):39-60 2004 Guide to Psychiatric Drug Interactions Sheldon H. Preskorn, MD, and David Flockhart, MD, PhD drug alone but is either more than or Focus Points less than what would normally be • In a drug-drug interaction (DDI), the presence of a second drug alters the expected for the specific dose ingested. nature, magnitude, or duration of the effect of a given dose of a first drug. “Altered duration” means that the These interactions can be therapeutic or adverse, planned or unintended, nature of the effect is reasonably the but are always determined by the pharmacodynamics and pharmacokinet- same as can be expected from the victim ics of the drugs involved rather than their therapeutic indication. drug alone, but the effect either is short- • The risk of unintended and untoward DDIs is increasing in concert with er or longer lived than would normally both the increasing number of pharmaceuticals available and the number of be expected for the dose given. patients on multiple medications. The goal of this guide is to provide a quick reference for prescribers about • To avoid adverse DDIs, the prescriber must keep in mind fundamental prin- some of the major psychiatric DDIs. ciples of pharmacology and good clinical management. Furthermore, it presents general con- • The prescriber must know all of the medications that the patient is taking cepts which can aid prescribers in and be able to use available knowledge about their pharmacodynamic and avoiding untoward DDIs when possible pharmacokinetic mechanisms to minimize the risk of untoward DDIs.
  • Procedure Codes, Section 3

    Procedure Codes, Section 3

    NEW YORK STATE MEDICAID PROGRAM PHYSICIAN – PROCEDURE CODES SECTION 3 - DRUGS and DRUG ADMINISTRATION Physician – Procedure Codes , Section 3- Drugs and Drug Administration _____________________________________________________________________________ Table of Contents GENERAL RULES AND INFORMATION ............................................................2 MMIS DRUG MODIFIERS ....................................................................................4 DRUGS.................................................................................................................5 IMMUNE GLOBULINS...................................................................................................5 VACCINES, TOXOIDS ..................................................................................................5 HYDRATION, THERAPEUTIC, PROPHYLACTIC AND DIAGNOSTIC INJECTIONS AND INFUSIONS (EXCLUDES CHEMOTHERAPY) .....................................................8 DRUGS ADMINISTERED OTHER THAN ORAL METHOD.........................................10 CHEMOTHERAPY ADMINISTRATION.......................................................................19 CHEMOTHERAPY DRUGS.........................................................................................21 Version 2008 – 1 (5/15/2008) Page 1 of 23 Physician – Procedure Codes , Section 3- Drugs and Drug Administration _____________________________________________________________________________ GENERAL RULES AND INFORMATION 1. BY REPORT: A service that is rarely provided, unusual, variable,
  • Injectable Medication Hcpcs/Dofr Crosswalk

    Injectable Medication Hcpcs/Dofr Crosswalk

    INJECTABLE MEDICATION HCPCS/DOFR CROSSWALK HCPCS DRUG NAME GENERIC NAME PRIMARY CATEGORY SECONDARY CATEGORY J0287 ABELCET Amphotericin B lipid complex THERAPEUTIC INJ HOME HEALTH/INFUSION** J0400 ABILIFY Aripiprazole, intramuscular, 0.25 mg THERAPEUTIC INJ J0401 ABILIFY MAINTENA Apriprazole 300mg, IM injection THERAPEUTIC INJ J9264 ABRAXANE paclitaxel protein-bound particles, 1 mg J1120 ACETAZOLAMIDE SODIUM Acetazolamide sodium injection THERAPEUTIC INJ J0132 ACETYLCYSTEINE INJ Acetylcysteine injection, 10 mg THERAPEUTIC INJ ACTEMRA INJECTION (50242-0136-01, J3262 50242-0137-01) Tocilizumab 200mg, 400mg THERAPEUTIC INJ ACTEMRA 162mg/0.9ml Syringe (50242- J3262 SELF-INJECTABLE 0138-01) Tocilizumab, 1 mg J0800 ACTHAR HP Corticotropin injection THERAPEUTIC INJ Hemophilus influenza b vaccine (Hib), PRP-T conjugate (4- 90648 ACTHIB dose schedule), for intramuscular use THERAPEUTIC INJ IMMUNIZATIONS J0795 ACTHREL Corticorelin ovine triflutal THERAPEUTIC INJ J9216 ACTIMMUNE Interferon gamma 1-b 3 miillion units SELF-INJECTABLE CHEMO ADJUNCT* J2997 ACTIVASE Alteplase recombinant, 1mg THERAPEUTIC INJ HOME HEALTH/INFUSION** J0133 ACYCLOVIR SODIUM Acyclovir, 5 mg THERAPEUTIC INJ HOME HEALTH/INFUSION** 90715 ADACEL Tdap vaccine, > 7 yrs, IM THERAPEUTIC INJ IMMUNIZATIONS J2504 ADAGEN Pegademase bovine, 25 IU THERAPEUTIC INJ HOME HEALTH/INFUSION** J9042 ADCETRIS Brentuximab vedotin Injection THERAPEUTIC INJ CHEMOTHERAPY J0153 ADENOCARD Adenosine 6 MG THERAPEUTIC INJ J0171 ADRENALIN Adrenalin (epinephrine) inject THERAPEUTIC INJ J9000 ADRIAMYCIN Doxorubicin
  • Multiple Medications

    Multiple Medications

    Unless specifically noted, Medications need to be discontinued for 48 hours prior to exam and 24 hours post exam ALL OVER THE COUNTER SUPPLEMENTS OFF FOR 5 DAYS (examples: papaya enzymes, turmeric, cinnamon, vit. E, etc.) Abilify Asprin- 24 hours ConZip Abciximab- 24 hours Atomoxetine Coumadin- 5 days Acetophenazine Aventyl Cyclobenzaprine Actremra- 5 days Azilect Cycloserine Actron- 24 hours Bayer Asprin- 24 hours Cyclosporine Adapin Benzphentamine Cylert Adderall Bextra-24 hours Cymbalta Adipenx Bontril Dabigatran Advil- 24 hours Brilinta- 5 days Dalteparin- 5 days Aflaxin- 24 hours Brufen- 24 hours Daypro- 24 hours Aggrenox- 7 days Brupropion Dayrun- 24 hours Aleve- 24 hours Busiprone Daytrana Algix – 24 hours BuSpar Demerol Alka Seltzer- 24 hours Cambia-24 hours Desipramine Amantadine Cataflam- 24 hours Desoxyn Amitriptyline Ceeoxx- 24 hours Desvenlafaxine Amitriptyline + Chlordiazepoxide Celebrex- 24 hours Desyrel Amitriptyline + Perphenazine Celecoxib- 24 hours Dexedrine Amoxapine Celexa Dexketoprofen- 24 hours Amphetamine Ceoxx- 24 hours Dexmethylphenidate Amphetamine mixture Chlorpromazine Dextroamphetamine Amrix Chlorprothixene Diclofenac- 24 hours Anafranil Cilostazol- 5 days Didrex Anaprox- 24 hours Citalopram Diethylprophm Ansaid- 24 hours Clinoril- 24 hours Diflunisal- 24 hours Apixaban- Clomipramine Disalcid- 24 hours Aripiprazole Clopidogrel- 5 days Dividose Arixtra- 5 days Clopidogrel Bisulfate- 5 days Dolobid- 24 hours Armodafinil Clotam Rapid- 24 hours Dopram Arthrotec-24 hours Clozapine Doxapram Asaid-24 hours Clozaril
  • Myelogram-Medications-To-Avoid.Pdf

    Myelogram-Medications-To-Avoid.Pdf

    Medication to be held 48 Banaflex /skeletal muscle relaxer Clozaril/antischizophenia HOURS BEFORE AND 24 HOURS Bancap/contains caffei Cogentin/antidyskinectic/ant AFTER MYELOGRAM Banzel/seizure adjunct iemetic/antipsychotic Updated December 2016 BC powder/ contains caffeine Compazine/phenothiazine Belviq/appetite suppressant Concerta/CNS stimulant Abilify / antipsychotic Bevespi contains formoterol Contrave/antidepressant Acetophenazine/ antipsychotic Benzphetamine/appetite Cyclizine/ antiemetic Adderall/amphetamine and suppressant antivertigo agent dextroamphetamine Bismuth subcitrate potassium/ Cyclobenzaprine/muscle Adipex-P/stimulant/ anorectic mineral relaxer Adsuva/antidepressant Bonine/meclicine Cylert/ADHD agent Adphen/ /antidepressant Bontril/appetite suppressant Cymbalta/antidepressant/tri appetite suppressant Bontril PDM/appetite suppressant cyclic Adipost/ appetite suppressants, Bortezomib/antineoplastics Sympathomimetic (Systemic Brintxelli / antidepressant Adrafinil/cognitive enhancer Bucladin-S softab/antiemetic Dapex/appetite suppressant Alatrofloxacin/ antibacterial antivertigo Dayquil/contains caffeine Aliskiren Bucet/contains caffeine Darvon 65/contain caffeine Hemifumarate/antihypertensive Buclizine/antiemetic/antivertigo Daytrana/CNS stimulant direct renal inhibitor / Budeption/antidepressant Desipramine/tricyclic/antide Alsuma/s Buphenamine/appetite suppressant pressant Amaphen/ barbituate Buproban/antidepressantr Desoxyn/amphetamine Amitriptyline/ tricyclic BupropionBuffets/caffeine Desvenlafaxine succinate/ antidepressant
  • TEXAS RACING COMMISSION January 28, 2021 To

    TEXAS RACING COMMISSION January 28, 2021 To

    TEXAS RACING COMMISSION P. O. Box 12080, Austin, Texas 78711-2080 8505 Cross Park Drive, Suite 110, Austin, Texas 78754-4552 Phone (512) 833-6699 Fax (512) 833-6907 www.txrc.texas.gov January 28, 2021 To: Stewards, Commission Veterinarians, Test Barn Supervisors, Practicing Veterinarians, Owners, and Trainers From: Chuck Trout, Executive Director Re: Effective February 25, 2021 changes to the following documents: • Permissible Levels of Therapeutic Medications and Naturally Occurring Substances • Equine Medication Classification Policy and Penalty Guidelines • Equine Medication Classification List. This memo is to provide notice that the above listed documents are to be replaced effective this date. The changes include, but are not limited to: • Changes to the list of Permissible Levels of Therapeutic Medications and Naturally Occurring Substances; • Changes to the Equine Medication Classification Policy and Penalty Guidelines; • Changes to the Equine Medication Classification List. These documents are subject to further revision at any time. Test Barn Supervisors - please post this memo and the revised documents in the test barn as soon as possible. Also, please distribute copies of the Permissible Levels of Therapeutic Medications and Naturally Occurring Substances and Equine Medication Classification List to the practicing veterinarians at your racetrack. Licensing Staff - please post this memo and the revised documents where they may be viewed by the public as soon as possible. Copies of these documents will be made available on the Commission's website at http://www.txrc.texas.gov. Attachments: Permissible Levels of Therapeutic Medications and Naturally Occurring Substances Equine Medication Classification Policy and Penalty Guidelines Equine Medication Classification List TEXAS RACING COMMISSION P.
  • New Information of Dopaminergic Agents Based on Quantum Chemistry Calculations Guillermo Goode‑Romero1*, Ulrika Winnberg2, Laura Domínguez1, Ilich A

    New Information of Dopaminergic Agents Based on Quantum Chemistry Calculations Guillermo Goode‑Romero1*, Ulrika Winnberg2, Laura Domínguez1, Ilich A

    www.nature.com/scientificreports OPEN New information of dopaminergic agents based on quantum chemistry calculations Guillermo Goode‑Romero1*, Ulrika Winnberg2, Laura Domínguez1, Ilich A. Ibarra3, Rubicelia Vargas4, Elisabeth Winnberg5 & Ana Martínez6* Dopamine is an important neurotransmitter that plays a key role in a wide range of both locomotive and cognitive functions in humans. Disturbances on the dopaminergic system cause, among others, psychosis, Parkinson’s disease and Huntington’s disease. Antipsychotics are drugs that interact primarily with the dopamine receptors and are thus important for the control of psychosis and related disorders. These drugs function as agonists or antagonists and are classifed as such in the literature. However, there is still much to learn about the underlying mechanism of action of these drugs. The goal of this investigation is to analyze the intrinsic chemical reactivity, more specifcally, the electron donor–acceptor capacity of 217 molecules used as dopaminergic substances, particularly focusing on drugs used to treat psychosis. We analyzed 86 molecules categorized as agonists and 131 molecules classifed as antagonists, applying Density Functional Theory calculations. Results show that most of the agonists are electron donors, as is dopamine, whereas most of the antagonists are electron acceptors. Therefore, a new characterization based on the electron transfer capacity is proposed in this study. This new classifcation can guide the clinical decision‑making process based on the physiopathological knowledge of the dopaminergic diseases. During the second half of the last century, a movement referred to as the third revolution in psychiatry emerged, directly related to the development of new antipsychotic drugs for the treatment of psychosis.